Subscribe

Evotec SE (EVT.DE)

EUR3.48 -0.27 (-7.25%)
DE XETRA Healthcare Drug Manufacturers - Specialty & Generic
Address Essener Bogen 7 22419
Hamburg, DE
CEO Christian Wojczewski
Website evotec.com
IPO 1999-11-12
ISIN DE0005664809

Explore sections of this company profile

Also trades on Deutsche Börse · EVT.DE (EUR) International Order Book · 0IRF.IL (EUR) NASDAQ Global Select · EVO (USD) Other OTC · EVOTF (USD) Swiss Exchange · EVT.SW (EUR)
Description

Evotec SE functions as a global collaborator, aiding the pharmaceutical and biotechnology industries in the identification and progression of novel drug candidates. The firm is actively engaged in advancing medicinal products designed to treat a diverse array of health challenges, including diabetes and its related complications, various fibrotic conditions, infectious diseases, disorders of the central nervous system, oncological conditions, pain management, inflammatory and immunological ailments, rare diseases, respiratory illnesses, and women's health concerns. Evotec SE has forged partnerships with a number of significant players in the sector, such as Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. The company, initially incorporated as Evotec AG in 1993, underwent a name change to Evotec SE in April 2019 and maintains its corporate headquarters in Hamburg, Germany.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR3.48 -0.27 (-7.25%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
754.6K
Beta
1.30
Float Shares
133.55M
Free Float %
75.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
0.00% -6.14% +14.79% -10.81% -3.35% -6.81% -29.25% -72.53% -84.24% +38.67% -66.79%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (5 ratings, all time) Buy
Price Targets & DCF
Current price
3.48
Ratings Trend (MoM) 57% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 3 0
Hold 3 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
0.26
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -1.1% Q1'26: -21.7% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +47.8% ★ Q1'26: -283.3% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    -20.8% Q1'26: -4.0% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    -17.9% Q1'26: -35.4% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    -18.0% Q1'26: -34.5% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.2% Q1'26: +0.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    -10.81× Q1'26: -1.75× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.30) × ERP
WACC = 68% × Ke + 32% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 3.48
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
8 Rev. Ana.
4 EPS Ana. 		Dec 2027
10 Rev. Ana.
4 EPS Ana. 		Dec 2028
7 Rev. Ana.
5 EPS Ana. 		Dec 2029
3 Rev. Ana.
1 EPS Ana. 		Dec 2030
6 Rev. Ana.
1 EPS Ana.
Revenue
80.13M
est: 79.95M (+0.2%)
87.27M
est: 90.37M (-3.4%)
85.94M
est: 88.36M (-2.7%)
89.50M
est: 92.68M (-3.4%)
127.68M
est: 125.03M (+2.1%)
164.51M
est: 155.80M (+5.6%)
257.63M
est: 244.72M (+5.3%)
375.41M
est: 371.69M (+1.0%)
446.44M
est: 428.79M (+4.1%)
500.92M
est: 479.44M (+4.5%)
618.03M
est: 578.42M (+6.8%)
751.45M
est: 723.44M (+3.9%)
781.43M
est: 788.44M (-0.9%)
796.97M
est: 794.44M (+0.3%)
788.37M
est: 788.85M (-0.1%)
750.67M
720.44M – 776.51M
-4.8% YoY
822.14M
732.95M – 971.50M
+9.5% YoY
892.30M
886.40M – 898.20M
+8.5% YoY
937.15M
865.80M – 1.04B
+5.0% YoY
986.18M
911.10M – 1.10B
+5.2% YoY
EBITDA
13.90M
est: 16.63M (-16.4%)
4.51M
est: 12.77M (-64.7%)
-14.07M
est: 1.76M (-899.3%)
5.00M
est: -17.62M (+128.4%)
24.93M
est: 7.73M (+222.6%)
45.57M
est: 31.61M (+44.2%)
35.50M
est: 74.96M (-52.6%)
105.88M
est: 56.55M (+87.3%)
86.77M
est: 113.55M (-23.6%)
90.36M
est: 110.27M (-18.1%)
298.41M
est: 125.59M (+137.6%)
-86.08M
est: 141.90M (-160.7%)
7.82M
est: 35.41M (-77.9%)
-80.66M
est: 35.75M (-325.6%)
-41.40M
est: 35.43M (-216.8%)
33.72M
32.36M – 34.88M
-4.8% YoY
36.93M
32.92M – 43.64M
+9.5% YoY
40.08M
39.81M – 40.34M
+8.5% YoY
42.09M
38.89M – 46.80M
+5.0% YoY
44.29M
40.92M – 49.25M
+5.2% YoY
EBIT
7.11M
est: 2.50M (+184.3%)
-4.31M
est: 5.88M (-173.3%)
-23.23M
est: -3.13M (-642.5%)
-4.71M
est: -22.45M (+79.0%)
14.22M
est: -8.60M (+265.3%)
34.47M
est: 14.71M (+134.4%)
26.83M
est: 49.45M (-45.7%)
74.59M
est: 57.34M (+30.1%)
37.96M
est: 89.93M (-57.8%)
34.31M
est: 68.95M (-50.2%)
230.80M
est: 78.52M (+193.9%)
-167.74M
est: 88.72M (-289.1%)
-92.10M
est: -59.14M (-55.7%)
-182.28M
est: -59.71M (-205.3%)
-140.87M
est: -59.17M (-138.1%)
-56.31M
-58.25M – -54.04M
+4.8% YoY
-61.67M
-72.87M – -54.98M
-9.5% YoY
-66.93M
-67.37M – -66.49M
-8.5% YoY
-70.29M
-78.16M – -64.94M
-5.0% YoY
-73.97M
-82.25M – -68.34M
-5.2% YoY
Net Income
6.75M
est: 4.86M (+38.9%)
2.48M
est: 7.57M (-67.3%)
-25.43M
est: 2.44M (-1,140.4%)
-6.98M
est: -26.64M (+73.8%)
16.52M
est: -9.41M (+275.6%)
27.53M
est: 20.87M (+31.9%)
24.26M
est: 43.43M (-44.2%)
84.17M
est: 36.65M (+129.7%)
38.16M
est: 97.72M (-61.0%)
6.28M
est: 41.94M (-85.0%)
215.51M
est: 47.76M (+351.2%)
-175.66M
est: -103.30M (-70.0%)
-83.91M
est: -170.69M (+50.8%)
-196.08M
est: -155.53M (-26.1%)
-103.52M
est: -77.59M (-33.4%)
-117.22M
-181.44M – -62.80M
-51.1% YoY
-32.28M
-37.63M – 252.9K
+72.5% YoY
45.80M
19.35M – 70.61M
+241.9% YoY
60.68M
54.68M – 69.51M
+32.5% YoY
77.25M
69.60M – 88.48M
+27.3% YoY
SGA
15.76M
est: 23.55M (-33.1%)
16.30M
est: 17.86M (-8.7%)
16.60M
est: 15.94M (+4.1%)
17.99M
est: 17.41M (+3.3%)
25.17M
est: 24.25M (+3.8%)
27.01M
est: 31.80M (-15.0%)
42.38M
est: 42.62M (-0.6%)
57.01M
est: 66.17M (-13.8%)
66.43M
est: 66.19M (+0.4%)
77.21M
est: 73.30M (+5.3%)
105.45M
est: 83.48M (+26.3%)
156.19M
est: 94.32M (+65.6%)
169.61M
est: 156.89M (+8.1%)
188.20M
est: 158.40M (+18.8%)
128.73M
est: 156.97M (-18.0%)
149.37M
143.36M – 154.52M
-4.8% YoY
163.60M
145.85M – 193.32M
+9.5% YoY
177.56M
176.38M – 178.73M
+8.5% YoY
186.48M
172.29M – 207.34M
+5.0% YoY
196.24M
181.30M – 218.19M
+5.2% YoY
EPS
0.06
est: 0.07 (-10.9%)
0.02
est: 0.06 (-67.6%)
-0.21
est: 0.03 (-798.9%)
-0.05
est: -0.03 (-73.1%)
0.13
est: 0.08 (+53.9%)
0.20
est: 0.10 (+99.4%)
0.16
est: 0.23 (-30.6%)
0.57
est: 0.36 (+57.8%)
0.25
est: 0.25 (-1.1%)
0.04
est: 0.16 (-74.8%)
1.30
est: 1.48 (-12.2%)
-0.99
est: -0.72 (-38.1%)
-0.47
est: -0.96 (+51.2%)
-1.11
est: -0.87 (-28.1%)
-0.58
est: -0.43 (-35.8%)
-0.67
-1.02 – -0.35
-57.4% YoY
-0.12
-0.21 – 0.00
+82.8% YoY
0.21
0.11 – 0.40
+281.7% YoY
0.34
0.31 – 0.39
+63.0% YoY
0.44
0.39 – 0.50
+27.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-11 B- 2/5 5/5 1/5 1/5 2/5 1/5 4/5
2026-05-08 B- 3/5 5/5 1/5 1/5 3/5 1/5 4/5
2026-05-07 B- 3/5 5/5 1/5 1/5 3/5 1/5 4/5
2026-05-06 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-05-05 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-05-04 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-04-30 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-04-29 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-04-28 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-04-27 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-04-24 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-04-23 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-04-22 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-04-21 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-04-20 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-04-17 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-04-16 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-96.87M
OE per share TTM
-0.55
Owner's Yield
-10.21%
Maintenance CapEx ratio
81.81%
Maint CapEx / Avg PPE
83.2%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
1
Total invested
56.0K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2025 Q3
Investors holding
1
+0 vs prev Q
New positions
0
Closed positions
0
Increased
0
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
# Investor ⇅ Shares / Δ ⇅ Mkt value / Δ ⇅ Own% / Δ ⇅ Weight% / Δ ⇅ Avg px / Perf. ⇅ Hold / Status ⇅
1 OLD MISSION CAPITAL LLC — -15.4K (-100.0%) — -56.0K (-100.0%) 0.00% -0.009 pp 0.00% -0.001 pp EUR— 3 qtrs SOLD
Ownership breakdown by holder

ETF Ownership

Top ETFs holding this stock Held by 87 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Amundi SDAX UCITS ETF Dist C005.DE 2.05% 3.67M 0.70%
2 Amundi TecDAX UCITS ETF Dist E908.DE 0.67% 625.3K 0.40%
3 iShares TecDAX UCITS ETF (DE) EXS2.DE 0.66% 4.65M 0.51%
4 iShares TecDAX UCITS ETF (DE) EXIB.DE 0.66% 85.5K 0.51%
5 Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist MMS.PA 0.24% 1.73M 0.40%
6 iShares MSCI EMU Small Cap UCITS ETF CES1.L 0.13% 1.35M 0.58%
7 UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE 0.13% 935.6K 0.33%
8 iShares Healthcare Innovation UCITS ETF HEAL.L 0.10% 1.13M 0.40%
9 Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA 0.09% 291.6K 0.23%
10 Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE 0.09% 291.6K 0.23%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-29.6K
Shares Outstanding
177.59M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Christian Wojczewski CEO & Chairperson of the Management Board 2M —
Paul Hitchin Chief Financial Officer & Member of Management Board 1M male
Aurelie Dalbiez Chief People Officer & Member of Management Board 958.0K female
Cord Dohrmann Chief Scientific Officer & Member of Management Board 763.0K —
Ian Hunneyball Senior Vice President of Programme Management & Clinical Operations 116.0K —
David Hallet Executive Vice President — —
Guy Rachmuth Senior VP of Global Strategic Business Development & Partnerships — —
Philip Boehme Executive Vice President of Partnering & Transformation — —
Sarah Fakih Executive VP, Head of Global Communications & Investor Relations — —
Uwe Andag EVP Head of Metabolic Diseases — —
Bernd Mühlenweg Senior VP & Head of Global Business Development — male
Christian Dargel EVice President Global Head of Legal & Compliance — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic